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The mam immunogemc region (MIR) of the acetylcholine receptor (AChR) is the target for the majority of high-affinity autoantibodtes produced 
in myasthenia gravis patients. Some monoclonal antibodies (mAbs) to the MIR bmd specifically, but with low affinity, to synthetic AChR a subunit 
peptides with the sequence ~67-76. Studies of synthetic peptides suggest that ammo acids a68 and a71 may be especially important to the antigenic 
structure of the MIR. We have studted the contribution of amino acids a68 and a71 to the anttgemcity of the MIR on intact AChR by replacing 
a68 (N) and a71 (D) of Torpedo AChR IX with a68 (D) and x71 (K) by site-directed mutagenests, expressmg the mutated transcripts in Xenopus 
oocytes along with wild-type Torpedo 8, 7 and b subumts. and analyzing the expressed AChR for the binding of mAbs to the MIR. These mutations 
of the MIR greatly dtmimshed bmding of mAbs to the MIR. Thus, both ~68 and a71 are crtttcal to the antigemcity of the MIR in intact AChRs. 
Acetylchohne receptor: Myasthenia gravis; Immunodommant region; Mutagenesis, in vitro; Subunit expression; Xenopus oocyte 
1. INTRODUCTION 
Nicotinic acetylcholine receptors (AChRs) from mus- 
cle and Torpedo electric organ are composed of 4 dif- 
ferent subunits in the stoichiometry a@$ [l]. In the 
human neuromuscular disease myasthenia gravis (MG), 
autoantibodies are directed against AChRs and cause 
accelerated destruction and functional blockage of 
AChRs which causes failure of neuromuscular 
transmission and muscular weakness (reviewed in [2]). 
A similar autoimmune disease called experimental 
autoimmune MG (EAMG) can be induced in animals 
that are immunized with purified AChR [3]. More than 
60% of the antibodies in sera of MG patients and rats 
with EAMG are directed at the main immunogenic 
region (MIR) on the AChR CY subunit [4-61. When in- 
jected into rats, monoclonal antibodies (mAbs) to the 
MIR induce an EAMG response, and when added to 
cultured muscle cells they cause loss of AChRs [7,8], 
further showing the importance of this region in the 
pathogenesis of MG. 
the amino acids ~~68 (asparagine, N) and 71 (aspartic 
acid, D) in Torpedo AChR cy subunits [19]. Synthetic 
peptides corresponding to Xenopus ~~66-76 did not 
bind mAbs to the MIR, whereas the corresponding 
Torpedo sequence did [ 141. Asparagine cu68 is critical to 
rnAb binding to the peptides because the human se- 
quence (~68-76 binds MIR mAbs, but ~~69-76 does not 
[14]. Residues cu68 and ~~71, among others, were also 
found to be important for binding of MIR mAbs when 
amino acid residues in synthetic peptides corresponding 
to human ~~67-76 were sequentially replaced by glycine 
and tested for antigenicity of the MIR [13]. 
Electron microscopy studies showed that the MIR is 
located on the extracellular surface of a subunits of the 
intact AChR [9]. Some mAbs to the MIR bind with low 
affinity but great specificity to synthetic peptides with 
the sequence ~~66-76 on Torpedo a subunits [lo-161. 
Xenopus muscle AChR is unique among muscle-type 
AChRs tested in not reacting with anti-MIR mAbs [ 171. 
In Xenopus AChR LY subunits [18] residues a68 (aspar- 
tic acid, D) and 71 (lysine, K) are quite different from 
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The MIR epitope is highly conformation dependent 
[4,20]. mAbs to the MIR bind to synthetic peptides 
with much lower affinity than to native AChRs, and in 
some cases they do not bind at all to denatured subunits 
or synthetic peptides [4,14]. Synthetic peptides do not 
reflect the conformation seen in the native AChR. 
Therefore, it is uncertain to what degree the detailed 
binding characteristics of mAbs to synthetic peptides of 
MIR reflect the real binding characteristics of mAbs to 
native AChRs. To begin determining which amino 
acids are important to the antigenic structure of the 
MIR in vivo, in the present study we replaced a68 and 
(~71 amino acid residues of Torpedo AChR LY subunits 
with the corresponding residues of Xenopus CY subunit 
by in vitro mutagenesis. Analysis of the mutated AChR 
subunit expressed in Xenopus oocytes along with 
‘Torpedo p, y and 6 subunits showed that changing 
either cr68 or a71 or both amino acids of Torpedo (Y 
subunits to the corresponding Xenopus amino acids 
eliminates binding of mAbs to the MIR in the expressed 
,4ChRs. Because the mutation inhibited binding of 
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even mAbs that depend strongly on the native confor- 
mation of the MIR and do not bind to synthetic pep- 
tides, these results show that the MIR is a compact 
region in the intact LY subunit that depends strongly on 
residues ~68 and a71 for its antigenicity. 
in V,tro Mutagenesis ot the MIR 
2. MATERIALS AND METHODS 
2.1. General methods and supplres 
The characterization of the mAbs has previously been described 
[4,6,10,21]. Radioiodmatlons were done by the chloramme-T method 
as described by Lindstrom et al. [22]. The Torpedo AChR subunits 
cloned under the control of the SP6 promoter in SP64T vector [23] 
(SP64T cy, d, 3, 6) were a generous gift from Dr Tom Claudio (Yale 
University). All chemicals were obtained from Sigma (St. Louis, 
MO), and frogs were obtained from NASCO (Fort Atkinson, U’l). 
2.2. In pilro mutagenesis 
An m vitro mutagenesis technique, shghtly modlfled from that of 
Kammann et al. [24], usmg the polymerase cham reaction (PCR) was 
used to generate the mutants ubmg the SP64T w clone as a template 
(as shown in Fig. 1). Two successive PCR steps were used (Fig. 1). In 
the first step the sequence between the ‘mutagenic primer’ (mm) and 
the ‘SP6 primer’ (SP6) was amplified. The mutagenic primer con- 
sisted of the mismatched nucleotide(s) at the MIR flanked by 10 
nucleotides complementary to the Torpedo LY sequence. The SP6 
primer consisted of the sequence complementary to the SP6 promoter 
which LS located 130 bp 5’ of the AChR cy coding sequence on SP64T 
cy. In the second PCR, the amplified fragment was used as a primer 
in combination with primer 3 (P3). P3 consisted of 20 bases com- 
plementary to the Torpedo cy sequence located between 373 and 393 
bases 3’ to the MIR. Thus, the product of the second PCR was the 
amplified sequence between the SP6 primer and P3, and it contained 
the desired mutation(s). This amplified product was digested with 
HrndIIl and DraIII restrlction enzymes. which cut the SP64T cy clone 
on oppostte sides of the MIR, with HlndIII on the 5’ side and DraIlI 
on the 3’ side. The dlgested fragment was then used to replace the 
unmutated HindlII/DraIII fragment of SP64T LY sequence. The 
nucleotide sequence between the HIndI and &a111 restriction sttes 
of the mutant clones was determmed using the dideosy method to 
confirm the desired ba,e change and also to make sure that no 
anomalies in the sequence had been generated by PCR. 
iv Ligation 
MIR 0 mutant 
Fig. 1. In vitro mutagenesis of MIR. 
2.3. Expressron of AChR m oocyres 
An in vitro transcription system using the SP6 RNA polymerase 
[25] was used to generate mRNA transcrtpts from Torpedo AChR 
subunit clones (SP64T LY, fi, 3. and 6). Oocytes were prepared for 
rmcroinjectlon as described by Colman [26], mjected with -1.6 ng 
RNA of each subunit, and incubated at 19°C for 2-3 days for AChR 
expression. The number of AChRs capable of bindmg [lzsI]~u- 
bungarotoxin (cuBgt) on the surface of the oocyte was measured by 
incubating the oocytes mdividually with 200 pl of 2 nM [‘*‘I]~Bgt in 
Barth’s solution [26] for 2 h at 19”C, washing the oocytes 4 times In 
3 ml of Barth’s solution, and measurmg the radioactivIty by 7 coun- 
ting. Oocyte lysates were prepared by homogenizing the oocytes m 
lysis buffer (50 mM Tris, 100 mM NaCI, 100 mM KF, 5 mhl EDTA, 
5 mM EGTA, 1.5% Triton X-100. 0.05% SDS, pH 7.5), incubatmg 
the homogenate at 4°C for 30 min, and clearmg debris by centrifuga- 
tion in a mlcrofuge at 4°C for 30 mm. Radtotmmunoassay (RIA) was 
used to test for mAb bindmg. Oocyte Iysates (containing lo-20 fmol 
of aBgt binding sites) were incubated at 4°C overnight with 2 nM 
[‘ZSI)~Bgt, 0.5 FM of test mAb, and 5 pl normal rat serum in 100 pl 
final volume of lysis buffer. Following a 2 h mcubatlon at 4°C with 
lOO,zl goat anti-rat IgCi, the sample was diluted with 1 ml of 
phosphate-buffered saline containmg 0.5% Triton X-100 (PBS- 
Triton), centrifuged, the pellet washed with 1 ml of PBS-Triton, and 
the radioactivity in the pellet measured by 7 counting. For sucrose 
gradient analysis, 100~1 of the oocyte lysate (from 10 oocytes) was 
sedimented on a 5 ml 5%20% sucrose gradlent at 65k rpm in a VTi 
65.2 rotor for 70 min at 4”C, and fractions (140 al) were collected on 
microtiter plates precoated with mAb 142. Followmg an overmght in- 
cubation at 4°C with 2 nM [“51]LuBgt m lysls buffer, the microwells 
were washed 4 times with 200rl of PBS-Triton and radtoactivlty 
measured by 7 counting. Precoating of mIcrotIter plates was ac- 
complished by applying 50~1 of 10 mM sodium carbonate buffer, 
pH 8.8, contaming 40 /g/ml mAb 142 to each well, incubating the 
plates at 4°C overnight. and quenching with 200 ~‘1 of PBS containing 
0.05% Tween-20 and 2% BSA for 2 h at room temperature 
3. RESULTS 
3.1. In vitro mutagenesis and the expression of MIR 
mutants 
Amino acids cr68 (N,AAT) and a71 (D,GAT) of the 
Torpedo AChR cy subunit were replaced individuallv 
(~~68 or a71 mutants) or in tandem (~~68 +71 mutant) 
with the corresponding residues a68 (D,GAT) and (~71 
(K,AAG), of Xenopus cvlb subunit [27] using a PCR 
mutagenesis technique. mRNA transcripts were 
prepared from the mutant subunits in vitro and injected 
into Xenopus oocytes in combination with transcripts 
of Torpedo wild-type p, y, and 6 AChR subunits. To 
assess the expression of the cx subunit mutants, oocyte 
lysates were prepared and were subjected to RIA in the 
presence of [‘2SI]~Bgt and mAb 142. mAb 142 binds to 
the cytoplasmic region of the Torpedo CY subunit away 
from the MIR [28]. Results showed that about 
9 fmol/oocyte of AChR were present in the oocytes 
56 
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that were injected with the ~68, a71 or a68+71 
mutants, in combination with p, y, and 6 subunits, as 
compared to -13 fmol/oocyte in oocytes that were in- 
jected with wild-type Torpedo subunits. The mutant 
AChRs were then analyzed for their insertion into the 
plasma membrane by testing for [12sI]~Bgt binding to 
the oocyte surface. Results showed that about 1.3 fmoi 
of trBgt binding sites were present on the surface of 
each oocyte that was injected with a68, ~71 or (~68 + 71 
mutants, in combination with the wild-type Torpedofi, 
y, and S subunits, as compared to -2 fmol of 
[‘251]aBgt binding sites on the oocytes that were in- 
jected with the wild-type AChR LY subunit. These 
results showed that mutation in (~68 and/or a71 did not 
prevent the assembly of the mutant cr subunits with 
native ,&, y, and 6 subunits, or prevent the insertion of 
the mutant AChRs in the surface membrane. 
To assess the proper association of the mutant cy 
subunits with the Torpedo p, y and 6 subunits, lysates 
from oocytes injected with the (r68 + 71, p, y, 6 com- 
binations and those injected with wild-type CX, p, y, S 
combinations were subjected to sucrose gradient 
sedimentation and the fractions were tested for 
[“‘I]crBgt binding (Fig. 2). Results showed that both 
the lysates from oocytes expressing the mutant AChR 
and the lysates expressing the wild-type AChR had the 
same gradient profile. Two toxin-binding peaks were 
present in each sample, a peak at position for AChR 
monomer (-9 S) and a peak at position for synthetic 
intermediates probably corresponding to combinations 
of CY with y and/or 6 subunits (M. Saedi, W.G. Conroy 
and J. Lindstrom, unpublished). 
3.2. Binding of MIR-specific mAbs to mutant AChRs 
Having established that mutations in Torpedo (Y 
subunit at ~68, a71, or a68 + 71 do not greatly affect 
the association of the G! subunit with@, y and 6 subunits 
or the insertion of the mutant AChRs into the surface 
membrane of Xenopus oocytes, we tested the effect of 
these mutations on the binding of MIR-specific mAbs. 
Lysates of the oocytes expressing these mutant AChRs 
were subjected to RIA in the presence of [‘251]aBgt, us- 
ing various mAbs. mAb 142, which binds to the 
cytoplasmic region of the cy subunit at @359-366 ([28], 
M. Das and J. Lindstrom, unpublished) which is dis- 
tant from the MIR, was used to quantitate the number 
of AChRs present in each lysate. Also, to eliminate any 
species-specific interactions that might exist between 
mAb and MIR mutants, the test mAbs were chosen 
from mAbs raised against different species. As seen in 
Fig. 3, mutations in ~~68, a71 or (r68+71 eliminated 
the binding of MIR-specific mAbs raised against 
AChRs from human (mAb 198), rodent (mAb 210), 
Torpedo (mAb 6), and Electrophor~s (mAbs 22 and 
47). mAb 35 is frequently used as the archetypic MIR 
mAb [5,7]. mAb 35 does not bind to synthetic peptides 
[12,14]. In muscle cells, cy subunits undergo a confor- 
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Fig. 2. Sucrose-gradient sedimentation analysis of mutant AChR. 
Lysates of oocytes Injected wtth transcrtpts of the Torpedo AChR 6, 
1. and 6 subunits m combinatton with the transcripts of the weld-type 
(0) or ~68 + 71 mutant form ( n f of Torpedo AChR CY subunit were 
sedimented on S-20% sucrose gradients and the fractions were tested 
for [“sI]uBgt binding as described in section 2. Each figure ts the 
average of duphcate gradients. Fracttons are numbered from the 
bottom of gradrents. The posnions of the monomer and the dimer 
forms of Torpedo AChR were determined from sucrose-gradtent 
analysis of lysates of Torpedo electrtc organ. 
&i 
0 a71 K 0 a68 D. 7, K 
cl.5 
1 
-._-._a 198 22 35 42 47 6 
Truman Rodent Electrophorus Torpedo 
mAbs to the MIR raised agamst various species 
Fig. 3. Binding of anti-MIR mAbs to mutant AChRs. Bindmg of the 
indicated mAbs to the AChRs expressed in oocytes Injected with 
wild-type or MIR mutants of Torpedo AChR N subunits in 
combination with the Torpedo p, 3, and 6 subunits was measured by 
RIA. For each sample, results were first calculated as binding of test 
mAbs relattve to the binding of mAb 142, and were then expressed 
as mean of trrplicates t SE refative to the bindmg of test mAbs to 
the wild-type sample (lOO%t. The background, lysates of noninjected 
oocytes subjected to RIA, was subtracted from each sample before 
calculattons. 
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mational maturation after synthesis and before 
assembly with other subunits, during which they ac- 
quire the ability to bind mAb 35 with high affinity 
([29], W.G. Conroy and J. Lindstrom, unpublished). 
Mutation of cu68 to the Xenopus residue reduced bin- 
ding of mAb 35, and the corresponding mutations at 
~71 or ru68 + 71 ~Iiminated binding of mAb 35. 
4. DISCUSSION 
In the autoimmune disease MC, more than 60% of 
the autoantibodies are directed against the MIR of the 
AChR [4,5]. Therefore, detailed investigation of 
antigen-antibody interactions at this region is critical 
for the understanding of the pathogen&s of MC. 
Several laboratories, including ours, have used syn- 
thetic or bacterially expressed peptides to monitor the 
critical amino acid residues involved in the binding of 
MIR-specific mAbs to this region [lo-16,301. These in 
vitro studies, however, cannot accurately reflect the in- 
teractions that exist between the antigens and an- 
tibodies in the native molecule, thereby necessitating 
the investigations of mAbs with the MIR on intact 
AChRs. 
To accomplish this we chose to mutagenize the 
Torpedo a! subunit and study the expression of the mu- 
tant a~ subunits in Xenopus oocytes, Resuits presented 
here show that converting ~68 (N) or ~~71 (D) amino 
acids to their respective residues in Xe~opus, (~68 (D) 
and ~71 (K), inhibited the binding of the MIR-specific 
mAbs while not greatly affecting the expression of 
AChRs containing the mutant LY subunit. Sucrose gra- 
dient analysis showed that the same size cuBgt-binding 
molecules are synthesized in oocytes injected with 
(~68 + 7 1, ,A!?, y, 6 combinations as oocytes injected with 
the wild-type subunits, indicating that the association 
of the cy subunit with B, T, and S subunits is not greatly 
affected by these mutations. This indicates that normal 
expression, NBgt binding, and subunit assembly of 
Torpedo AChR are not absolutely dependent on the 
native conformation of the MIR. 
Binding studies using MIR-specific mAbs showed 
that a68 and ~71 were critical for binding of all mAbs 
to the MIR tested. This correlates well with the finding 
that binding of these mAbs to synthetic peptides con- 
taining the (~67-76 sequence is inhibited when cu68 or 
a71 is substituted by glycine [13]. Results also showed 
that mutations in either (~68 or (~71 inhibited the bin- 
ding of anti-Electrophorus mAbs 22 and 47. This is 
particularly interesting since glycine substitution for 
a68 or cy71 in human ~~67-76 synthetic peptide did not 
have any effect on the binding of mAbs 22 or 47 to the 
oligopeptide. We cannot explain this apparent 
discrepancy, but it suggests that binding of mAbs 22 
and 47 to native AChR cx is dependent on the confor- 
mation of the MIR and that interactions of mAbs with 
58 
synthetic peptides do not always reflect in detail their 
interactions with native AChRs. 
The importance of MIR conformation in mAb bin- 
ding is evident from mAb 35 binding studies. mAb 35 
binding is highly conformation dependent and it does 
not bind to synthetic peptides [12,14,31]. Our results 
show that converting au68 (N) to tu68 (D) reduces the 
binding of this antibody to AChR and that converting 
(~71 (D) to ~71 (K) eliminates it. This suggests that mAb 
35 binding is less dependent on the individual amino 
acid residues within the MIR, but more dependent on 
the overall conformation of this region. Thus, a more 
drastic change in the charge of the amino acid at ~~71, 
substituting K (basic) for D (acidic), affects the confor- 
mation of the MIR, and thereby mAb 35 binding, more 
drastically than a more subtle change in the charge of 
the amino acid at ~~68, substituting D (acidic) for N 
(neutral). This finding also suggests that in cases of 
other anti-MIR mAbs, the binding depends more on 
the nature of the amino acid at cu68 than on the overall 
conformation of the MIR. 
Studies of the crystal structures of complexes of an- 
tibodies with lysozyme reveal that many (-18) amino 
acids of the antigen may be in contact with the antibody 
binding site [32], but that many of these interactions 
are permissive and that alteration of a single, critical 
amino acid can greatly alter the affinity of the antibody 
for the protein [33]. Our results are consistent with 
these observations. Our results also suggest that the 
MIR is not a series of closely spaced epitopes that allow 
competitive binding of WAbs because each occludes a 
large area of AChR (perhaps 35 A in diameter [4,33]), 
but rather that the MIR is a single, compact epitope 
[3 l] in which amino acids ~~68 and a71 are critically im- 
portant to the interaction of this structure with many 
mAbs which may bind to the MIR in slightly different 
ways. 
Further studies using simiiar mutagenesis and expres- 
sion of human AChR cx subunits 134,353 may permit 
better definition of the specificities of autoantibodies to 
AChRs from MC patients. 
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